Amyris (Amyris) ROCE %

: -234.62% (As of Mar. 2023)

View and export this data going back to 2010. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Amyris's annualized ROCE % for the quarter that ended in Mar. 2023 was -234.62%.

Amyris ROCE % Historical Data

The historical data trend for Amyris's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amyris Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-925.99

-66.30

-91.58

Amyris Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
ROCE %	Get a 7-Day Free Trial															-63.80	-67.34	-122.87	-130.64	-234.62

Amyris ROCE % Calculation

Amyris's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-513.892	/	( ( (954.298 - 269.805)	+	(824.932 - 387.147) )	/ 2 )
	=	-513.892	/	( (684.493	+	437.785)	/ 2 )
	=	-513.892	/	561.139
	=	-91.58 %

Amyris's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	-758.612	/	( ( (824.932 - 387.147)	+	(679.679 - 470.794) )	/ 2 )
	=	-758.612	/	( ( 437.785	+	208.885 )	/ 2 )
	=	-758.612	/	323.335
	=	-234.62 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

Amyris (OTCPK:AMRSQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Amyris ROCE % Related Terms

Thank you for viewing the detailed overview of Amyris's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Amyris (Amyris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Amyris Inc (OTCPK:AMRSQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5885 Hollis Street, Suite 100, Emeryville, CA, USA, 94608

Website

https://www.amyris.com

Amyris Inc is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of products in a variety of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The business operations are spread across the world with the majority of the revenues generated in the United States. The company generates revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants, and collaborative research and development services.

Executives

J. Scott White	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip J. Gund	officer: Chief Restructuring Officer	C/O SUNEDISON, INC., 13736 RIVERPORT DR., MARYLAND HEIGHTS MO 63043
M. Freddie Reiss	director	2951 28TH STREET, SUITE 1000, SANTA MONICA CA 90405
Hermanus Kieftenbeld	officer: Chief Financial Officer	259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Eduardo Alvarez	officer: Chief Operating Officer	AMYRIS, INC., 5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
Elizabeth E. Dreyer	officer: CHIEF ACCOUNTING OFFICER	EDGEWELL PERSONAL CARE, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Frank Kung	director	C/O VIVO CAPITAL, 505, PALO ALTO CA 94301
Nicole Kelsey	officer: General Counsel and Secretary	AMYRIS, INC., 5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
John Melo	director, officer: President and CEO	C/O AMYRIS, INC., 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Anthony Hughes	officer: Chief Accounting Officer	5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
Ana Dutra	director	C/O KORN/FERRY INTERNATIONAL, 1900 AVENUE OF THE STARS, SUITE 2600, LOS ANGELES CA 90067
James F Mccann	director	ONE OLD COUNTRY ROAD, SUITE 500, CARLE PLACE NY 11514
Ryan Panchadsaram	director	5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
L John Doerr	director, 10 percent owner	C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Julie Washington	director	C/O JAMBA, INC., 6475 CHRISTIE AVENUE, NO. 150, EMERYVILLE CA 94608